Trisomy

When deciding whether traditional prenatal screening for trisomy is worth potential complications, including loss of the foetus, expectant parents can find themselves facing a difficult dilemma. Luckily, there are now safer alternatives to amniocentesis that offer close to 100% accurate risk assessment. Our non-invasive prenatal screening procedure is an innovative genetic test for pregnant women at risk of fetal Patau syndrome, Edward's Syndrome, or Down syndrome. These rapid, reliable and safe NIPT tests quickly and effectively detect trisomy 13, 18 and 21, and can be carried out by your healthcare provider. Available starting from only the 10th week of pregnancy, they offer true peace of mind.

The NIPT trisomy tests offered by Eurofins Biomnis efficiently detect factors of abnormal pregnancy by drawing a small maternal blood sample. Aside from maternal DNA, the blood of pregnant women contains fetal DNA originating from the placenta. The identification of fetal DNA in the maternal blood sample, in tandem with a new technology called Next Generation Sequencing that is capable of counting all genetic material sequences in the sample, permits the rapid and accurate detection of abnormalities including fetal Patau syndrome (trisomy 13) and Down syndrome (trisomy 21). With a more than 99% detection rate, these trisomy tests may allow you to limit or entirely forgo invasive screening procedures.

While many patients might assume that trisomy screening is necessarily a complicated procedure, this innovative non-invasive prenatal screening (NIPT) kit is remarkably simple to prescribe and administer. The procedure can be prescribed by your healthcare provider, and you can have the simple blood test taken at your physician's office or at aEurofins Biomnis partner laboratory. It can be taken quite early in your pregnancy, after only 10 weeks ofpregnancy. With results of the blood test available after 7 working days, NIPT by Eurofins Biomnis is an efficient, safe and remarkably accurate new way to undergo trisomy screening. It has been found to reduce unnecessary invasive sampling by up to 95%.